Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081889 | SCV000113824 | uncertain significance | not provided | 2013-01-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000807227 | SCV000947270 | uncertain significance | Cohen syndrome | 2022-09-06 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 949 of the VPS13B protein (p.Ile949Met). This variant is present in population databases (rs398124331, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 95842). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
New York Genome Center | RCV000807227 | SCV002764318 | uncertain significance | Cohen syndrome | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002514437 | SCV003743223 | uncertain significance | Inborn genetic diseases | 2021-06-04 | criteria provided, single submitter | clinical testing | The c.2847A>G (p.I949M) alteration is located in exon 20 (coding exon 19) of the VPS13B gene. This alteration results from a A to G substitution at nucleotide position 2847, causing the isoleucine (I) at amino acid position 949 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000807227 | SCV001454819 | uncertain significance | Cohen syndrome | 2020-09-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004742250 | SCV005348715 | uncertain significance | VPS13B-related disorder | 2024-05-03 | no assertion criteria provided | clinical testing | The VPS13B c.2847A>G variant is predicted to result in the amino acid substitution p.Ile949Met. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.028% of alleles in individuals of European (Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |